SCHEMBL8738404

SCHEMBL8738404

C=CC(=O)OCCCCCC(=O)OCCOCCOC(=O)CCCCCOC(=O)C=C

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 7/20 0.66
ALDH1A1 P00352 5/20 0.66
TP53 P04637 3/20 0.66
HIF1A Q16665 3/20 0.66
CYP3A4 P08684 2/20 0.66
HSD17B10 Q99714 1/20 0.66
HPGD P15428 1/20 0.50
DGKA P23743 1/20 0.47
THRB P10828 2/20 0.46
EPHX2 P34913 1/20 0.39
PRSS1 P07477 1/20 0.39
PRSS2 P07478 1/20 0.39
PRSS3 P35030 1/20 0.39
DNM1 Q05193 1/20 0.37
LMNA P02545 1/20 0.36
HTR2C P28335 1/20 0.36
NAAA Q02083 1/20 0.35
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL276446 0.95 TSHR (0.73) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL12558002 0.95 TSHR (0.73) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL5476493 0.94 TSHR (0.58) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL11233083 0.93 TSHR (0.76) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL19165635 0.91 TSHR (0.65) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL19627098 0.91 TSHR (0.65) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL9100632 0.89 TSHR (0.83) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL2534124 0.89 TSHR (0.61) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL23553096 0.89 DGKA (0.66) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL14792967 0.89 DGKA (0.66) TSHRALDH1A1TP53HIF1ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11697804-B2 Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy THE JOHNS HOPKINS UNIVERSITY (US) 2023-07-11 US disclosed
US-20180177881-A1 Multicomponent Degradable Cationic Polymers THE JOHNS HOPKINS UNIVERSITY 2018-06-28 US disclosed
US-20180134753-A1 BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES THE JOHNS HOPKINS UNIVERSITY 2018-05-17 US disclosed
US-20180112038-A1 POLY(BETA-AMINO ESTER)-CO-POLYETHYLENE GLYCOL (PEG-PBAE-PEG) POLYMERS FOR GENE AND DRUG DELIVERY THE JOHNS HOPKINS UNIVERSITY (US) 2018-04-26 US disclosed
US-9884118-B2 Multicomponent degradable cationic polymers THE JOHNS HOPKINS UNIVERSITY (US) 2018-02-06 US disclosed
US-20180028455-A1 PEPTIDE/PARTICLE DELIVERY SYSTEMS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-02-01 US disclosed
US-9802984-B2 Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases THE JOHNS HOPKINS UNIVERSITY (US) 2017-10-31 US disclosed
US-9717694-B2 Peptide/particle delivery systems THE JOHNS HOPKINS UNIVERSITY (US) 2017-08-01 US disclosed
US-20170143639-A1 NANOCOMPOSITES OF GOLD AND POLYMERS THE JOHNS HOPKINS UNIVERSITY (US) 2017-05-25 US disclosed
US-20160374949-A9 PEPTIDE/PARTICLE DELIVERY SYSTEMS THE JOHNS HOPKINS UNIVERSITY (US) 2016-12-29 US disclosed
US-20160122390-A1 A BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES THE JOHNS HOPKINS UNIVERSITY (US) 2016-05-05 US disclosed
US-20150273071-A1 Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery THE JOHNS HOPKINS UNIVERSITY (US) 2015-10-01 US disclosed
US-20150272900-A1 Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics THE JOHNS HOPKINS UNIVERSITY 2015-10-01 US disclosed
US-20150250881-A1 Multicomponent Degradable Cationic Polymers THE JOHNS HOPKINS UNIVERSITY (US) 2015-09-10 US disclosed
US-8992991-B2 Multicomponent degradable cationic polymers THE JOHNS HOPKINS UNIVERSITY (US) 2015-03-31 US disclosed
US-20140294909-A1 NANOCOMPOSITES OF GOLD AND POLYMERS THE JOHNS HOPKINS UNIVERSITY (US) 2014-10-02 US disclosed
US-20120128782-A1 Multicomponent Degradable Cationic Polymers THE JOHNS HOPKINS UNIVERSITY (US) 2012-05-24 US disclosed
US-20120114759-A1 PEPTIDE/PARTICLE DELIVERY SYSTEMS THE JOHNS HOPKINS UNIVERSITY (US) 2012-05-10 US disclosed
US-20070031499-A1 Readily shapeable xerogels having controllably delayed swelling properties AKINA, INC. 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160374949-A9 PEPTIDE/PARTICLE DELIVERY SYSTEMS VEGFA, IAPP, FLT1 TSHR 2490/4885ALDH1A1 4007/4885TP53 324/4885
US-20160122390-A1 A BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES VEGFA, LRRFIP1, FLT1 TSHR 2524/4885ALDH1A1 3688/4885TP53 1814/4885
US-20150272900-A1 Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics DNMT3L, DBNL, HNRNPL TSHR 2581/4885ALDH1A1 2087/4885TP53 892/4885
US-20150250881-A1 Multicomponent Degradable Cationic Polymers PEF1, FIBP, PARN TSHR 3568/4885ALDH1A1 3684/4885TP53 65/4885
US-20070031499-A1 Readily shapeable xerogels having controllably delayed swelling properties SMARCA2, SMARCA4, SMARCE1 TSHR 1677/4885ALDH1A1 4329/4885TP53 1189/4885
US-20180177881-A1 Multicomponent Degradable Cationic Polymers PEF1, FIBP, PARN TSHR 3568/4885ALDH1A1 3684/4885TP53 65/4885
US-20170143639-A1 NANOCOMPOSITES OF GOLD AND POLYMERS HNRNPL, HNRNPLL, ACSL3 TSHR 1764/4885ALDH1A1 883/4885TP53 1592/4885
US-20150273071-A1 Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery AARS1, SLC43A1, PHAX TSHR 4597/4885ALDH1A1 3187/4885TP53 1588/4885
US-20120114759-A1 PEPTIDE/PARTICLE DELIVERY SYSTEMS VEGFA, IAPP, FLT1 TSHR 2490/4885ALDH1A1 4007/4885TP53 324/4885
US-20180112038-A1 POLY(BETA-AMINO ESTER)-CO-POLYETHYLENE GLYCOL (PEG-PBAE-PEG) POLYMERS FOR GENE AND DRUG DELIVERY PBDC1, BCAT1, PBRM1 TSHR 3297/4885ALDH1A1 2856/4885TP53 178/4885
US-20120128782-A1 Multicomponent Degradable Cationic Polymers PEF1, FIBP, PARN TSHR 3568/4885ALDH1A1 3684/4885TP53 65/4885
US-20180134753-A1 BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES VEGFA, LRRFIP1, FLT1 TSHR 2635/4885ALDH1A1 3587/4885TP53 1625/4885
US-11697804-B2 Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy POLRMT, HDGF, PCNP TSHR 3981/4885ALDH1A1 3433/4885TP53 15/4885
US-20180028455-A1 PEPTIDE/PARTICLE DELIVERY SYSTEMS VEGFA, IAPP, FLT1 TSHR 2490/4885ALDH1A1 4007/4885TP53 324/4885
US-20140294909-A1 NANOCOMPOSITES OF GOLD AND POLYMERS HNRNPL, HNRNPLL, ACSL3 TSHR 1764/4885ALDH1A1 883/4885TP53 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.